Multiple Myeloma News

 
 
  • Statins Have Benefits in Multiple Myeloma New findings point to a potential role for statin drugs in patients with multiple myeloma.
  • PCOS ‘Groundbreaking’ Palliative Care Study: Not Just for Dying Palliative care improved outcomes in a curative setting and reduced the morbidity associated with hematopoietic stem cell transplantation.
  • Daratumumab Improves PFS in Multiple Myeloma Daratumumab added to bortezomib and dexamethasone improves progression-free survival (PFS) in patients with relapsed or refractory multiple myeloma (MM), according to results from the CASTOR trial.
  • Overweight/Obesity Linked to Eight More Cancers Having excess body fat has already been linked to an increase in the risk for five cancer types -- now another eight cancer types are added to the list.
  • Venetoclax Shows Promise in Acute Myelogenous Leukemia Venetoclax monotherapy appears to improve outcomes in some patients with acute myelogenous leukemia (AML), according to a phase 2, single-arm study.
  • Costs of Treating Blood Disorders Explored The costs of treating hematologic malignancies and nonmalignant blood disorders are similar, but there is substantial variation in direct healthcare costs between countries.
  • Revlimid Fails to Extend Survival in Lymphoma Study Celgene Corp said on Monday that its flagship drug Revlimid (lenalidomide) failed to extend survival as a maintenance therapy for a type of blood cancer after patients had responded to prior treatment.
  • Early Treatment of Smoldering Myeloma: Is It Time? The combination lenalidomide and dexamethasone has been shown to delay the progression of smoldering multiple myeloma. So should this approach be used in clinical practice?
  • Ipilimumab Shows Impressive Activity After HSCT Failure In patients with hematologic malignancies, ipilimumab, the CTLA4 inhibitor, showed impressive responses after disease relapse following allogeneic transplant.
  • Lenalidomide Combination Trumps Older Drugs for Multiple Myeloma Lenalidomide plus dexamethasone more effectively treats newly diagnosed multiple myeloma patients ineligible for stem-cell transplantation, regardless of age, than a triplet of older drugs, researchers report.
  • ASCO Lenalidomide Maintenance 'Clear Standard' After Transplant Lenalidomide maintenance therapy after stem cell transplant in multiple myeloma increases survival compared with placebo, a new meta-analysis confirms.
  • ASCO New Triplet Therapy in Multiple Myeloma A new triplet therapy has shown high responses with manageable tolerability in newly diagnosed multiple myeloma.
  • EHA Latest Daratumumab Results Herald 'New Era' in Myeloma Another daratumumab trial shows benefit in relapsed myeloma, with the highest response rates ever seen; the findings herald a 'new era of immunotherapies,' says expert.
  • ASCO Daratumumab Combo: New Standard of Care in Multiple Myeloma A three-drug regimen that includes daratumumab doubled response rates and markedly reduced risk for progression, compared with standard therapy.
  • Sunday at ASCO: Plenary Shows Progress in Myeloma Among the best clinical data selected for the plenary session is the CASTOR study, showing impressive progression-free survival in multiple myeloma.
  • FDA-Approved Cancer Drugs That Are 'Deeply Problematic' The US Food and Drug Administration wants to expedite the availability of cancer drugs. But is this a good idea when full approval is based on an unproven, unexamined surrogate end point?
  • ASCO Transplant Still Best Up-front Option in Myeloma Treatment options for myeloma have dramatically increased, but at least for right now, transplant should remain the preferred treatment for younger patients.
  • Thalidomide Maker Hushed up Drug's Side Effects, German Report Says The firm that invented thalidomide, a drug that caused birth defects in thousands of babies, carried out a deliberate disinformation campaign when experts first spotted possible severe side effects, a report commissioned by the German state of North-Rhine Westphalia (NRW) said on Friday.
  • Independent Group Finds Multiple Myeloma Drugs Too Costly in US U.S. prices for newer multiple myeloma cancer treatments should be cut by as much as 94 percent to justify their value in terms of prolonging life, while there is not enough evidence to assess the health benefit of some, according to an independent nonprofit organization that evaluates the effectiveness of medicines.
  • Ixazomib in First All-Oral Triplet for Multiple Myeloma The trial showing efficacy for ixazomib in the first oral triplet regimen for the treatment of relapsed, refractory multiple myeloma has now published.
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.